作者
Menno V Huisman, Kenneth J Rothman, Miney Paquette, Christine Teutsch, Hans-Christoph Diener, Sergio J Dubner, Jonathan L Halperin, Chang Sheng Ma, Kristina Zint, Amelie Elsaesser, Dorothee B Bartels, Gregory YH Lip
发表日期
2017/2/21
期刊
Journal of the American College of Cardiology
卷号
69
期号
7
页码范围
777-785
出版商
American College of Cardiology Foundation
简介
Background
GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non–vitamin K antagonist oral anticoagulant (NOAC), became available.
Objectives
This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1.
Methods
During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients’ baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics …
学术搜索中的文章
MV Huisman, KJ Rothman, M Paquette, C Teutsch… - Journal of the American College of Cardiology, 2017